on GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
GenSight Biologics raises 500,000 euros to strengthen its development
GenSight Biologics, a biopharmaceutical company pioneering gene therapies, announced €500,000 in funding from one of its existing shareholders. This fundraising follows a previous €4 million round in early July 2025.
The additional financial resources are intended to support LUMEVOQ, GenSight's flagship drug, currently in Phase III, and to prepare for its compassionate access program in France, scheduled for the end of 2025. This funding also guarantees the continuation of operations until October 2025.
UPMC Enterprises' support demonstrates confidence in GenSight's long-term potential. This financial momentum aims to solidify the company's position in the neurodegenerative disease treatment market.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENSIGHT BIOLOGICS S.A. news